GSK Pharma stock heads toward Q2 results after trading window closes

Published on 10/07/2026 at 04:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

GSK Pharma stock was last at INR 2,755 on October 6, 2026, with a 0.81 percent gain. Q1 FY27 revenue rose 16.52 percent and profit 15.61 percent year over year.

GSK Pharma, INE159A01016, Illustration mit AI erstellt.

GSK Pharma (ISIN INE159A01016) was last at INR 2,755 on the NSE on October 6, 2026, with a daily gain of 0.81 percent. The trading window closed on October 1 ahead of the second-quarter and first-half FY27 results for the period ended September 30, 2026.

Q2 results follow a stronger quarter

According to ScanXNews on September 25, 2026, the closure remains in force until 48 hours after the release of the unaudited Q2 and half-year figures. The notice links the restriction directly to the reporting period ended September 30, 2026, making the next results the central checkpoint for the stock.

The latest reported quarter provides a firm comparison base. Univest reported Q1 FY27 revenue of INR 938 crore, up 16.52 percent from INR 805 crore in Q1 FY26, while net profit increased 15.61 percent to INR 237 crore from INR 205 crore.

Revenue must recover from June

The Q1 figures also show why the September quarter matters. Revenue declined from INR 995 crore in Q4 FY26 to INR 938 crore in Q1 FY27, while net profit fell from INR 278 crore to INR 237 crore on a sequential basis.

For the year-over-year comparison, the September 2025 base was INR 980 crore of revenue and INR 257 crore of net profit, according to Univest. The Q2 release will therefore be read against both the 16.52 percent Q1 revenue growth rate and a demanding profit base from the prior-year quarter.

Consensus target sits above the stock

A four-analyst consensus published by Investing.com gives an average 12-month target of INR 3,081, with targets ranging from INR 2,870 to INR 3,500. Compared with the October 6 price of INR 2,755, the average target lies 11.8 percent above the stock.

GSK India describes the business as a focused biopharma company covering medicines and vaccines, with research centered on respiratory disease, immunology and inflammation, oncology, HIV and infectious diseases, according to its investor information. That portfolio breadth makes the Q2 margin and product mix as important as the headline revenue number.

GSK Pharma stock holds a wide range

GSK Pharma was last at INR 2,755 on October 6, 2026, after trading between INR 2,707 and INR 2,762.90 during the session. The 52-week range was INR 2,088.10 to INR 3,120.70, while market capitalization stood at INR 466.7 billion.